Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Cost-benefit considerations for TKI selection in CML

Hagop Kantarjian • 6 Sep 2023
SOHO 2023
Chronic Myeloid Leukemia Leukemia Bosutinib Dasatinib Imatinib Nilotinib Ponatinib

Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses cost-benefit considerations when choosing a tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML). Many TKIs are becoming generic, and Prof. Kantarjian highlights the importance of considering the aims of the treatment to aid in TKI selection. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hagop Kantarjian

Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial
1:16
Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial
Hagop Kantarjian • 6 Sep 2023
Unmet needs in CML: increasing treatment-free remission & accessibility to TKIs
1:22
Unmet needs in CML: increasing treatment-free remission & accessibility to TKIs
Hagop Kantarjian • 6 Sep 2023
Venetoclax, CLAD/LDAC and azacitdine in older AML patients
6:23
Venetoclax, CLAD/LDAC and azacitdine in older AML patients
Hagop Kantarjian • 30 Nov 2020
Ponatinib in chronic-phase CML patients with prior second generation TKI exposure
4:44
Ponatinib in chronic-phase CML patients with prior second generation TKI exposure
Hagop Kantarjian • 30 Nov 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals